These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

459 related items for PubMed ID: 24099468

  • 1. Review article: the association between nodular regenerative hyperplasia, inflammatory bowel disease and thiopurine therapy.
    Musumba CO.
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1025-37. PubMed ID: 24099468
    [Abstract] [Full Text] [Related]

  • 2. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine.
    Seksik P, Mary JY, Beaugerie L, Lémann M, Colombel JF, Vernier-Massouille G, Cosnes J.
    Inflamm Bowel Dis; 2011 Feb; 17(2):565-72. PubMed ID: 20848502
    [Abstract] [Full Text] [Related]

  • 3. Nodular Regenerative Hyperplasia of the Liver in Patients with IBD Treated with Allopurinol-Thiopurine Combination Therapy.
    Seinen ML, van Asseldonk DP, de Boer NK, Bouma G, van Nieuwkerk CM, Mulder CJ, Bloemena E, van Bodegraven AA.
    Inflamm Bowel Dis; 2017 Mar; 23(3):448-452. PubMed ID: 28151736
    [Abstract] [Full Text] [Related]

  • 4. Is there a role for thioguanine therapy in IBD in 2017 and beyond?
    Taylor KM, Ward MG, Blaker PA, Sparrow MP.
    Expert Rev Gastroenterol Hepatol; 2017 May; 11(5):473-486. PubMed ID: 28276819
    [Abstract] [Full Text] [Related]

  • 5. The prevalence of nodular regenerative hyperplasia of the liver in long-term thiopurine-treated inflammatory bowel disease patients.
    Gilissen LPL, Tajzai R, Romberg M, Pierik M, Stronkhorst A, Steenhuisen K, Van Bodegraven A, Daniels A, Wong D.
    Eur J Gastroenterol Hepatol; 2021 Dec 01; 33(1S Suppl 1):e102-e107. PubMed ID: 33136726
    [Abstract] [Full Text] [Related]

  • 6. Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
    Bayoumy AB, van Liere ELSA, Simsek M, Warner B, Loganayagam A, Sanderson JD, Anderson S, Nolan J, de Boer NK, Mulder CJJ, Ansari A.
    BMC Gastroenterol; 2020 Sep 11; 20(1):296. PubMed ID: 32917155
    [Abstract] [Full Text] [Related]

  • 7. Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.
    Simsek M, Meijer B, Ramsoekh D, Bouma G, van der Wouden EJ, den Hartog B, de Vries AC, Hoentjen F, Dijkstra G, de Boer SY, Jansen JM, van der Meulen AE, Beukers R, Brink MA, Steinhauser T, Oldenburg B, Gilissen LP, Naber TH, Verhagen MA, de Boer NKH, Mulder CJJ, Dutch Initiative on Crohn and Colitis (ICC).
    Clin Gastroenterol Hepatol; 2019 Feb 11; 17(3):568-570. PubMed ID: 29775790
    [Abstract] [Full Text] [Related]

  • 8. Histopathology of liver biopsies from a thiopurine-naïve inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia.
    De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA.
    Scand J Gastroenterol; 2008 Feb 11; 43(5):604-8. PubMed ID: 18415755
    [Abstract] [Full Text] [Related]

  • 9. [Nodular regenerative hyperplasia as a complication of thiopurine treatment in a patient with inflammatory bowel disease].
    Cohen-Ezra O, Avni Y, Morgenstern S, Ben-Ari Z.
    Harefuah; 2012 Dec 11; 151(12):675-8, 721. PubMed ID: 23330258
    [Abstract] [Full Text] [Related]

  • 10. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine.
    Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A, Duclos B, Seksik P, Mary JY, Colombel JF.
    Gut; 2007 Oct 11; 56(10):1404-9. PubMed ID: 17504943
    [Abstract] [Full Text] [Related]

  • 11. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy.
    Seiderer J, Zech CJ, Diebold J, Schoenberg SO, Brand S, Tillack C, Göke B, Ochsenkühn T.
    Eur J Gastroenterol Hepatol; 2006 May 11; 18(5):553-5. PubMed ID: 16607155
    [Abstract] [Full Text] [Related]

  • 12. Azathioprine induced nodular regenerative hyperplasia in IBD patients.
    Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol M, Coutarel P, Loison P, Jian R, Marteau P.
    Gastroenterol Clin Biol; 2005 May 11; 29(5):600-3. PubMed ID: 15980758
    [Abstract] [Full Text] [Related]

  • 13. The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.
    van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.
    Inflamm Bowel Dis; 2016 Sep 11; 22(9):2112-20. PubMed ID: 27482972
    [Abstract] [Full Text] [Related]

  • 14. 6-thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension.
    Ferlitsch A, Teml A, Reinisch W, Ulbrich G, Wrba F, Homoncik M, Gangl A, Peck-Radosavljevic M, Vogelsang H.
    Am J Gastroenterol; 2007 Nov 11; 102(11):2495-503. PubMed ID: 17894846
    [Abstract] [Full Text] [Related]

  • 15. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients.
    Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, Martin P, Vierling JM, Geller SA, Targan SR, Poordad FF.
    Gastroenterology; 2003 Aug 11; 125(2):298-303. PubMed ID: 12891528
    [Abstract] [Full Text] [Related]

  • 16. Assessment of non-cirrhotic portal hypertension associated with thiopurine therapy in inflammatory bowel disease.
    Calabrese E, Hanauer SB.
    J Crohns Colitis; 2011 Feb 11; 5(1):48-53. PubMed ID: 21272804
    [Abstract] [Full Text] [Related]

  • 17. Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety.
    Dubinsky MC.
    Clin Gastroenterol Hepatol; 2004 Sep 11; 2(9):731-43. PubMed ID: 15354273
    [Abstract] [Full Text] [Related]

  • 18. A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
    Kennedy NA, Rhatigan E, Arnott ID, Noble CL, Shand AG, Satsangi J, Lees CW.
    Aliment Pharmacol Ther; 2013 Nov 11; 38(10):1255-66. PubMed ID: 24117596
    [Abstract] [Full Text] [Related]

  • 19. The Effectiveness and Safety of First-Line Thioguanine in Thiopurine-Naïve Inflammatory Bowel Disease Patients.
    Crouwel F, Bayoumy AB, Mulder CJJ, Peters JHC, Boekema PJ, Derijks LJJ, de Boer SY, van de Meeberg PC, Ahmad I, Buiter HJC, de Boer NK.
    Inflamm Bowel Dis; 2024 Sep 03; 30(9):1492-1499. PubMed ID: 37658804
    [Abstract] [Full Text] [Related]

  • 20. Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
    Kader HA, Wenner WJ, Telega GW, Maller ES, Baldassano RN.
    J Clin Gastroenterol; 2000 Jun 03; 30(4):409-13. PubMed ID: 10875470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.